Clinical Trials
24 trialsNCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT05831995 2024-12-06
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
Phase 1 Terminated
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT02498665 2023-11-14
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT01904123 2022-03-23
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT03734913 2020-07-22
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT01522820 2016-10-04
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01131234 2014-12-23
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01273090 2014-01-30
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT00003022 2013-07-03
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00073944 2013-05-30
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed
NCT00002754 2013-02-20
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
Duke University
Phase 1 Completed
NCT01294735 2012-08-15
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00019019 2012-03-15
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed